<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3003">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04716556</url>
  </required_header>
  <id_info>
    <org_study_id>TSUNAMI</org_study_id>
    <nct_id>NCT04716556</nct_id>
  </id_info>
  <brief_title>TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients</brief_title>
  <official_title>TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa Due to SARS-CoV2 (TSUNAMI Study): a Multicenter Open Label Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Superiore di Sanità</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agenzia Italiana del Farmaco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Superiore di Sanità</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter open-label randomized study for the early treatment of pneumonia due to&#xD;
      SARS-COV2 with transfusion of convalescent plasma.&#xD;
&#xD;
      Patients with pneumonia due to SARS-CoV-2 will be randomized to receive or not convalescent&#xD;
      plasma collected by recovered patients with previous diagnosis of COVID19&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter open-label randomized study for the early treatment of pneumonia due to&#xD;
      SARS-COV2 with transfusion of convalescent plasma.&#xD;
&#xD;
      Patients with SARS-CoV2 pneumonia not requiring mechanical ventilation (both non invasive and&#xD;
      invasive) will be randomized to receive or not convalescent plasma.&#xD;
&#xD;
      Patients in the plasma group will receive 200-300 ml of plasma collected by recovered&#xD;
      patients with previous diagnosis of COVID19, plus standard therapy; Patients in the control&#xD;
      group will receive the standard therapy. A rescue therapy will be allowed in case of clinical&#xD;
      worsening.&#xD;
&#xD;
      Patients will be followed until day n30 from randomization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 16, 2020</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who meet invasive mechanical ventilation or death</measure>
    <time_frame>at 30 days</time_frame>
    <description>Number of patients who meet invasive mechanical ventilation defined as PaO2/FiO2 &lt;150 or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rates</measure>
    <time_frame>30 days</time_frame>
    <description>Mortality rates at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to invasive mechanical ventilation or death</measure>
    <time_frame>30 days</time_frame>
    <description>Days from randomization to invasive mechanical ventilation or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to virologic recover</measure>
    <time_frame>30 days</time_frame>
    <description>Days from randomization to virologic recover (defined as 2 consecutive negative nasopharynx tests)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization time</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>occurrence of Adverse events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of CD4/CD8 ratio</measure>
    <time_frame>14 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">474</enrollment>
  <condition>Covid19</condition>
  <condition>Coronavirus Infection</condition>
  <condition>Pneumonia, Viral</condition>
  <arm_group>
    <arm_group_label>Standard Therapy+Convalescent Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive standard therapy + 200-300 ml of convalescent plasma for a maximum of 3 times in 5 days, according to clinical conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive standard therapy for the treatment of SARS-CoV2 infection, according to AIFA indications</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Convalescent plasma</intervention_name>
    <description>Convalescent plasma will be collected by healthy donors, recovered by COVID19 and, after standard preparation and dosage of neutralizing antibodies, it will be administered to patients with SARS-CoV2 pneumonia</description>
    <arm_group_label>Standard Therapy+Convalescent Plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  adult patients with positive RT-PCR test for SARS-CoV2 (nasal swabs or lower&#xD;
             respiratory tract sample), diagnosed with pneumonia (&lt;= 10 days) according to the&#xD;
             following definitions:&#xD;
&#xD;
               -  Suggestive radiological imaging (CT, RX, ultrasound);&#xD;
&#xD;
               -  Respiratory failure not fully explained by heart failure or fluid overload;&#xD;
&#xD;
               -  PaO2/FiO2 200-350 mmHg;&#xD;
&#xD;
               -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  need of non invasive or invasive mechanical ventilation at the time of randomization;&#xD;
&#xD;
          -  PaO2/FiO2 &lt;200;&#xD;
&#xD;
          -  patients with hypersensitivity or allergic reaction to blood products or&#xD;
             immunoglobulins;&#xD;
&#xD;
          -  patients who expressly refuse to adhere the clinical study;&#xD;
&#xD;
          -  use of IL-6 Receptor inhibitors, IL-1 inhibitors, JAK inhibitors, TNF inhibitors;&#xD;
&#xD;
          -  patients participating to other clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ospedale Città di Castello</name>
      <address>
        <city>Città Di Castello</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O.C. Malattie Infettive ASL Frosinone</name>
      <address>
        <city>Frosinone</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Malattie Infettive IRCCS-Ospedale Policlinico San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.C. Pneumologia e Utir ASST Mantova - Ospedale Carlo Poma</name>
      <address>
        <city>Mantova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SC Malattie Infettive ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dip. Medicina Diagnost. e Servizi Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Perugia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Pisana</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pistoia</name>
      <address>
        <city>Pistoia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Prato</name>
      <address>
        <city>Prato</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Viareggio</name>
      <address>
        <city>Viareggio</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 14, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Superiore di Sanità</investigator_affiliation>
    <investigator_full_name>Elena Toschi</investigator_full_name>
    <investigator_title>Research Coordinator</investigator_title>
  </responsible_party>
  <keyword>plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

